Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$3.90 USD
+0.08 (2.09%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $3.89 -0.01 (-0.26%) 6:46 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CAPR 3.90 +0.08(2.09%)
Will CAPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CAPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CAPR
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
CAPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Other News for CAPR
Capricor Therapeutics’ Strong Potential Justifies Buy Rating Amidst Strategic Progress and Positive Clinical Developments
Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
Cantor Fitzgerald Remains a Buy on Capricor Therapeutics (CAPR)
Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)
Buy Rating Affirmed for Capricor Therapeutics Amidst Positive Drug Outlook and Strategic Advances